Publication
What M&A trends will transform the 2024 insurance landscape?
It is widely accepted that 2023 was one of the worst years in recent memory for M&A activity.
United States | Publication | April 2021
Federal OSHA has advised previously that employers can require the COVID-19 vaccination as a condition of employment. It has now released additional guidance for employers to clarify what this can mean in the real world.
Specifically, OSHA addresses the potential (albeit rare to date) of an employee who incurs an adverse reaction to a mandated vaccination. In such a situation, the reaction will be deemed "work-related."
The ultimate effect of this guidance is that if the adverse reaction involves days away from work, restricted work, transfer to another job or medical treatment beyond first aid, it will be considered a "recordable" incident. In other words, the reaction will be part of the record of serious work-related injuries and illnesses that OSHA requires most companies with more than 10 workers to maintain and make available to their employees.
By contrast, employers that simply recommend vaccination to their employees are not required to record an adverse reaction as work-related. OSHA notes that this distinction applies only if the vaccine is truly voluntary. Indeed, in this circumstance, OSHA states that, "[a]n employee who chooses not to receive the vaccine cannot suffer any repercussions from this choice."
It is also important to highlight that, under the OSHA guidance, an adverse reaction is not recordable even if an employee who was not required by the employer to be vaccinated still received the vaccine at work. The critical determination is whether the vaccination is a condition of employment.
See our other COVID-related guidance on our Health Law Pulse blog post, "COVID-19 Update: U.S. Centers for Disease Control and Prevention Updates Mask Guidelines."
Publication
It is widely accepted that 2023 was one of the worst years in recent memory for M&A activity.
Publication
The ongoing conflicts and further geopolitical tensions in Eastern Europe and the Middle East, coupled with upcoming elections in a number of key countries including the US and the UK, make 2024 challenging to predict what impact this will have on the insurance sector.
Publication
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the administrative stage of a legal saga that has attracted interest beyond competition law specialists.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023